FindTrial
Sign In

Optimal effect-site concentration of remifentanil for preventing cough

Optimal effect-site concentration of remifentanil for preventing cough during removal of the Double-lumen endotracheal tube from sevoflurane-remifentanil anesthesia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0001563
Enrollment
25
Registered
2015-07-09
Start date
2015-04-29
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Ajou University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: American Society of Anesthesiology physical status 1 and 2 patients, aged 20-65 years, undergoing video-assisted thoracoscopic lung lobectomy requiring one lung ventilation

Exclusion criteria

Exclusion criteria: Patients with administration of an angiotensin-converting enzyme inhibitor, anticipated difficult airway, patient with gastroesophageal reflux or asthma, chronic obstructive disease and upper respiratory infection

Design outcomes

Primary

MeasureTime frame
effect-site concentration of remifentanil for preventing cough during emergence after general anesthesia using double lumen tube—

Secondary

MeasureTime frame
hemodynamic data during emergence from general anesthesia—

Countries

Korea, Republic of

Contacts

Public ContactSung Yong Park

Ajou University Hospital

anepark@hanmail.net

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026